Cannabis Science Inc (OTCMKTS:CBIS) is trending in line like we thought. CBIS is coming out of their bear run. Friday, the cannabis company jumped up, and his holding gains at 15%.
This period to date saw their share price fall from about $0.09 to $0.028, a near 75% fall. Now, they are looking to rebound through their cannabis research and advanced relationships with the scientific/healthcare community. According to the company, they take advantage of their unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. They work with leading experts in drug development, medicinal characterization, and clinical research.
Cannabis Science Inc (OTCMKTS:CBIS) defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Find out when $CBIS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Besides an upcoming accelerated harvest, CBIS released a publication dubbed ‘Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids’, a piece of research that details the implication of cannabinols on the fight against cancer.
“This publication reflects our initial work and we are assiduously working on using our drug delivery system to examine the effect of cannabinoids with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the FDA.”
Currently holding at a market capitalization of $74.1M, CBIS is seeing a nice run to end the week. yet, we do see a reason for some optimism and could be a good candidate to watch as their research starts to be more clear. Over the two quarters of 2017, their financial position has improved in a few areas. Their net loss nearly halved, falling from $4 million to $2.3 million in a period when their research and development costs rose from $95,537 to $168,889, a near 80% increase. Sign-up for continuing coverage on shares of $CBIS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CBIS, either long or short, and we have not been compensated for this article.